FUSED IMIDAZOLE COMPOUNDS AND REMEDIES FOR DIABETES MELLITUS

Publication number: WO0102400

Publication date: 2001-01-11

Inventor: ASANO OSAMU (JP); HARADA HITOSHI (JP); YOSHIKAWA SEIJI (JP); WATANABE NOBUHISA (JP); INOUE TAKASHI (JP); HORIZOE TATSUO (JP); YASUDA NOBUYUKI (JP); OOHASHI KAYA (JP); MINAMI HIROE (JP); NAGAOKA JUNSAKU (JP); MURAKAMI MANABU (JP); KOBAYASHI SEIICHI (US); TANAKA ISAO (JP); KAWATA TSUTOMU (JP); SHIMOMURA NAOYUKI (JP); AKAMATSU HIROFUMI (JP); OZEKI NAOKI (JP); SHIMIZU TOSHIKAZU (JP); HAYASHI KENJI (JP); HAGA TOYOKAZU (JP); NEGI SHIGETO (JP); NAITO TOSHIHIKO (JP)

Applicant: EISAI CO LTD (JP); ASANO OSAMU (JP); HARADA HITOSHI (JP); YOSHIKAWA SEIJI (JP); WATANABE NOBUHISA (JP); INOUE TAKASHI (JP); HORIZOE TATSUO (JP); YASUDA NOBUYUKI (JP); OHASHI KAYA (JP); MINAMI HIROE (JP); NAGAOKA JUNSAKU (JP); MURAKAMI MANABU (JP); KOBAYASHI SEIICHI (US); TANAKA ISAO (JP); KAWATA TSUTOMU (JP); SHIMOMURA NAOYUKI (JP); AKAMATSU HIROFUMI (JP); OZEKI NAOKI (JP); SHIMIZU TOSHIKAZU (JP); HAYASHI KENJI (JP); HAGA TOYOKAZU (JP); NEGI SHIGETO (JP); NAITO TOSHIHIKO (JP)

Classification:

- international: ***A61P3/10; A61P43/00; C07D471/04; C07D473/00; C07D473/34; C07D473/40;*** **A61P3/00; A61P43/00; C07D471/00; C07D473/00;** (IPC1-7): C07D473/34; A61K31/437; A61K31/52; A61K31/522; A61P3/10; A61P43/00; C07D213/73; C07D213/75; C07D235/18; C07D239/48; C07D471/04; C07D471/08; C07D473/18; C07D473/40; C07D487/04

- European: C07D471/04; C07D473/00; C07D473/34; C07D473/40

Application number: WO2000JP04358 20000630

Priority number(s): JP19990188484 19990702; JP20000143495 20000516; JP20000182786 20000619

Also published as:

EP1221444 (A1)
WO0102400 (A1)
US6841549 (B1)
CA2376835 (A1)
EP1221444 (B1)

more >>

Cited documents:

JP11263789
WO9957103
JP10182636
WO9839344
US4728644

more >>

Report a data error here

Abstract of **WO0102400**

Novel fused imidazole compounds of general formula (I), pharmacologically acceptable salts thereof, or hydrates of both, exhibiting adenosine A2 receptor antagonism and being effective in the prevention and treatment of diabetes mellitus and complications of diabetes; wherein R<1> is optionally alkylated amino or the like; R<2> is hydrogen, alkyl, or the like; R<3> is optionally substituted aryl, a pyridinone group, a pyrimidinone group, or the like; Ar is an optionally sybstituted aryl or heteroaryl group, or the like; and Q and W are each independently N or CH.